The Long Run with Luke Timmerman

Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.

Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.

Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.

Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.

Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.

Reid Huber, partner at Third Rock Ventures, on investing in the future of medicine.

Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.

Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.

Turning the Tables, Rob Perez Interviews Me

Zach Weinberg and Alexis Borisy of Curie.Bio on Freeing the Biotech Founders

Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.

Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.

Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.

Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.

Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.

Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.

Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.

John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.

Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.

Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.

Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.

Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.

David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.

Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.

Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.

Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.

DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.

Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.

Shehnaaz Suliman, CEO of ReCode Therapeutics, on lipid nanoparticle delivery of genetic medicines.

Tariq Kassum, CEO of Cambridge, Mass.-based Celsius Therapeutics, on using single cell technology for drug discovery.

Aetna Wun Trombley, CEO of Lycia Therapeutics, on extracellular protein degraders.

Samantha Truex, CEO of Upstream Bio, on a new approach to treating severe asthma and other inflammatory diseases.

Tim Lu, CEO of Senti Biosciences, on developing gene circuits for cell therapy.

Jo Viney, CEO of Seismic Therapeutic, on discovering new treatments for autoimmune disease.

Ivan Liachko, CEO of Seattle-based Phase Genomics, on assembling accurate genomes and interactomes. He also discusses immigrating from Ukraine as a child, and what brought him and his family to the US.

Dr. Sanduk Ruit of the Tilganga Institute in Kathmandu on restoring eyesight with affordable cataract surgery for the developing world.

Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, on precision neuroscience drug development.

Rahul Singhvi, CEO of Resilience, on rethinking the model for manufacturing of advanced biologics, gene and cell therapies.

Chris Gibson, co-founder and CEO of Recursion, on using new tools to industrialize drug discovery.

Lewis Cantley and Siddhartha Mukherjee, co-founders of Faeth Therapeutics, on fighting cancer with food and drug combinations.

Bernat Olle, CEO of Vedanta Biosciences, on developing microbiome therapeutics.

Ray Stevens, CEO of ShouTi, on structural biology driven drug discovery.

Michele Andrasik, a clinical health psychologist at the Fred Hutchinson Cancer Research Center, on improving community outreach and diversity in clinical trials.

Derrell Porter, CEO of CellEvolve, on a new approach to commercializing cell therapies.

Praveen Tipirneni, CEO of Morphic Therapeutic, on targeting integrins with small molecules.

Bassil Dahiyat of Xencor on antibody engineering and company building.

Vineeta Agarwala, general partner with Andreesen Horowitz's bio fund, on investing in therapeutics, diagnostics and digital health.

Nello Mainolfi, CEO of Kymera Therapeutics, on targeted protein degrading small molecule drugs.

Jeff Bluestone, CEO of Sonoma Biotherapeutics, on engineered T-reg cell therapies for autoimmunity.

Ken Song, CEO of RayzeBio, on targeted radiopharmaceuticals for cancer.